{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:20Z","timestamp":1786120340125,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/bor.0b013e32835257c5","type":"journal-article","created":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T09:06:40Z","timestamp":1331716000000},"page":"290-298","source":"Crossref","is-referenced-by-count":35,"title":["Baseline predictors of response to TNF-\u03b1 blocking therapy in ankylosing spondylitis"],"prefix":"10.1097","volume":"24","author":[{"given":"Suzanne","family":"Arends","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"van der Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees G.M.","family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Spoorenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.24001","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.","volume":"59","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3899\/jrheum.081033","article-title":"Etanercept in the long term treatment of patients with ankylosing spondylitis.","volume":"36","author":"Dijkmans","year":"2009","journal-title":"J Rheumatol"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.","volume":"68","author":"Van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.","volume":"70","author":"Van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R6-8-20210128","first-page":"1000","article-title":"The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria Arthritis R","volume":"52","author":"Rudwaleit","year":"2005","journal-title":"heum"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/ard.2006.066415","article-title":"Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.","volume":"66","author":"Baraliakos","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/BOR.0b013e328133f5b3","article-title":"Osteoporosis and vertebral fractures in ankylosing spondylitis.","volume":"19","author":"Geusens","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/ard.2008.100503","article-title":"Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study.","volume":"68","author":"Vosse","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00198-010-1338-7","article-title":"The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis.","volume":"22","author":"Arends","year":"2011","journal-title":"Osteoporos Int"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis.","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASASEULAR recommendations for the management of ankylosing spondylitis.","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).","volume":"52","author":"Van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.24838","article-title":"Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of antitumor necrosis factor treatment in ankylosing spondylitis.","volume":"61","author":"De Vries","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2009.111187","article-title":"Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.","volume":"69","author":"Pedersen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","article-title":"Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.","volume":"49","author":"Lord","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with antitumour necrosis factor: results from 8 years surveillance in the Danish nationwide DANBIO registry.","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R25-8-20210128","first-page":"958","article-title":"Anti-TNF therapy of ankylosing spondylitis in clinical practice: results from the Czech national registry ATTRA.","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/acr.20258","article-title":"Presence of peripheral arthritis and male sex predicting continuation of antitumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.","volume":"62","author":"Kristensen","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R29-8-20210128","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to antitumour necrosis factor treatment in ankylosing spondylitis.","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy.","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol"},{"key":"R34-8-20210128","first-page":"2078","article-title":"C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis.","volume":"34","author":"Luc","year":"2007","journal-title":"J Rheumatol"},{"key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/ard.2010.138883","article-title":"ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors.","volume":"70","author":"Pedersen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/ard.2007.071605","article-title":"Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.","volume":"67","author":"Visvanathan","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R38-8-20210128","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.","volume":"68","author":"Van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10067-008-0941-x","article-title":"Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis.","volume":"27","author":"Romero-Sanchez","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R40-8-20210128","first-page":"1753","article-title":"Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.","volume":"34","author":"Woo","year":"2007","journal-title":"J Rheumatol"},{"key":"R41-8-20210128","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3899\/jrheum.101128","article-title":"Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.","volume":"38","author":"Arends","year":"2011","journal-title":"J Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e32835257c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:34:13Z","timestamp":1786048453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201205000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32835257c5","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}